

ABATTIS BIOCEUTICALS CORP.
NOTICE OF CHANGE OF AUDITOR

(National Instrument 51-102)

TO: Deloitte LLP
Dale Matheson Carr-Hilton Labonte LLP
British Columbia Securities Commission
Alberta Securities Commission
Ontario Securities Commission
Canadian Securities Exchange

Abattis Bioceuticals Corp. (the “**Company**”) gives the following notice (the “**Notice**”) in accordance with Section 4.11 of National Instrument 51-102 - *Continuous Disclosure Obligations* (“**NI 51-102**”) that;

- (a) at the request of the Company, Deloitte LLP, Chartered Professional Accountants (“**Deloitte**”), of 2800 – 1055 Dunsmuir Street, Vancouver, British Columbia, V7X 1P4, Canada, the predecessor auditor, tendered its resignation effective December 5, 2016;
- (b) the Company appointed Dale Matheson Carr-Hilton Labonte LLP, Chartered Professional Accountants (“**DMCL**”), of 1500 - 1140 West Pender St., Vancouver, BC V6E 4G1, as the successor auditor of the Company effective December 5, 2016;
- (c) Deloitte has not expressed any reservation or modified opinions in its report for the most recently completed fiscal year of the Company, nor for the period from the most recently completed period for which Deloitte issued an audit report in respect of the Company and the date of this Notice;
- (d) the resignation of Deloitte and the appointment of DMCL as auditor of the Company were considered and approved by the board of directors of the Company;
- (e) there was no “reportable event” cited by Deloitte in connection with the audit of the most recently completed fiscal year of the Company, nor for the period from the most recently completed period for which Deloitte issued an audit report in respect of the Company and the date of this Notice as defined in section 4.11(1) of NI 51-102; and
- (f) the content of this Notice has been reviewed by the board of directors of the Company.

[Remainder left blank intentionally]

Dated: December 5, 2016

ABATTIS BIOCEUTICALS CORP.

By: "Rene David"

Name: Rene David

Title: CFO